[1] Danan G, Bénichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol, 1993, 46(11): 1323-1330.
[2] Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci,2016,17(1):14.
[3] Hayashi PH, Isabel Lucena M, Fontana RJ, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology, 2022, 76(1):18-31.
[4] Lewis JH. Digitizing DILI: Who can? RUCAM? RECAM? Hepatology, 2022, 76(1): 3-5.
[5] Danan G, Teschke R. Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation. Hepatology, 2022, 76(1):E27.
[6] Fontana RJ, Liou I, Reuben A, et al. AASLD Practice Guidance on Drug, Herbal and Dietary Supplement Induced Liver Injury. Hepatology. 2022.Epub ahead of print.
[7] 赖荣陶,刘鸿凌,陈成伟,等. 2022版美国肝病学会(AASLD)关于药物及草药和膳食补充剂(HDS)所致肝损伤的指导建议.肝脏,2022,(8):835-841.
[8] 聂晓璐,彭亚光,孙子墨,等. 药物性肝损伤诊断相关生化指标阈值制定的研究现状及思考. 中国药物警戒,2022,19(3):244-247,258.
[9] 高广周,陈思文,万军. 肝样细胞模型在药物性肝损伤研究中的进展. 中华消化杂志,2022,42(1):62-65.
[10] Xu L, Yang Y, Wen Y, et al. Hepatic recruitment of eosinophils and their protective function during acute liver injury. J Hepatol,2022,77(2):344-352.
[11] Chen S, Lu Z, Jia H,et al. Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice. J Hepatol. 2022,S0168-8278(22)03285-8.
[12] Wang J, Song H, Ge F,et al. Landscape of DILI-related adverse drug reaction in China Mainland. Acta Pharm Sin B,2022,12(12):4424-4431.
[13] 赵鹏, 陈静, 杨光红, 等.住院结核患者抗结核药物性肝损伤的Nomogram风险预测模型构建 . 中华结核和呼吸杂志, 2022, 45(2) : 171-176.
[14] 杜静,王亚东,赵彩彦. 结核病初治患者药物性肝损伤危险因素的分析. 中华传染病杂志,2022,40(10):602-606.
[15] 王巧玲,梁庆生,黄昂,等. 255例肝穿刺证实的慢性药物性肝损伤患者预后的影响因素分析. 临床肝胆病杂志,2022,38(6):1334-1340.
[16] Wang JB, Huang A, Wang Y, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial. Aliment Pharmacol Ther,2022,55(10):1297-1310.?
[17] 陈红,赵莎莎,杨婉君. 慢性药物性肝损伤患者临床特征及转归分析. 肝脏,2022,27(6):679-682.
[18] 黄嘉敏,赵霞,孙宜康,等. 何首乌致药物性肝损伤的病理学特点. 肝脏,2022,27(1):20-22,37.
[19] 严微,黄会芳. 糖皮质激素治疗重症药物性肝损伤的效果分析. 临床肝胆病杂志,2022,38(10):2302-2307.
[20] 王轶,任经天. 苯溴马隆与药物性肝损伤的获益-风险分析和思考. 中国药物警戒,2022,19(2):189-192.
[21] 沈婷婷,李光耀,罗琼,等. 类风湿性关节炎患者应用雷公藤制剂及合并用药所致药物性肝损伤的临床特征分析. 临床肝胆病杂志,2022,38(9):2067-2072.
[22] 吴璟玲,陈晓君. 盐酸二甲双胍缓释片致重度肝损伤. 药物不良反应杂志,2022,24(5):264-265.
[23] 王芳,谢青,赖荣陶. 首乌藤致亚急性肝功能衰竭1例. 肝脏,2022,27(8):940-941.
[24] 于丽红,赵婷,马文明. 那屈肝素钙注射液致肝损伤. 药物不良反应杂志,2022,24(7):387-389.
[25] 苏琼丽,魏龙,吴玲. 赛瑞替尼致肝损伤1例. 肝脏,2022,27(10):1151-1152.
[26] 李晨,苏海滨,胡瑾华,等. 奥利司他胶囊致急性肝损伤和肾损伤. 药物不良反应杂志,2022,24(9):502-504.
[27] 范小飞,顾融融,殷晓芹. 地屈孕酮相关性肝损伤1例及文献复习. 中南药学,2022,20(1):235-237.
[28] 梁霄,沈姗,魏敦灿,等. 左乙拉西坦相关肝损伤文献病例分析. 药物不良反应杂志,2022,24(8):429-434.
[29] Tang J, Gu J, Chu N, et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. Liver Int, 2022,42(8):1803-1813. |
